Pádraig O'Sullivan

So the latest point is that basically Biogen came back with a price early in 2026.

That price wasn't acceptable to the NCP.

So Biogen were asked for further information.

They have since, as of about 10 days ago, have resubmitted that information.

So that is now with the HSE.

The HSE acknowledged that they received it on the 27th of May.

So what happens now is the NCP will review that and then they will make a recommendation to the drugs group.

And then the drugs group will consider that information and then they will make a recommendation to the HSE senior management team.

Well, that's what I said to you earlier.

I provided a timeline to your producer.

I totted up all the days since Sky Clarice was initially sought for reimbursement, which was August of 2024.

So you're looking at 500 days to get us to the point where we're at now.

What I'm saying is since it was applied for in August 2024, it's around 500 days to get us to this point.

I can't predict if it's going to take another month, two months, three months.

There could be further negotiation for all I know.

I don't know what Biogen have resubmitted as their price.

I can't predict whether that price is going to be acceptable to the NCPE.

Yes.

And the reason I say it is because for me, it can feel like Groundhog Day.

I first got involved with rare diseases in 2020, 2021 when I was a newly elected TD.